Surzetoclax, also known as ABBV 453; is a highly potent and selective BCL-2 inhibitor with a Ki of approximately 0.07 nM. It induces apoptosis in BCL-2–dependent hematologic cancer cells, showing EC50 values typically below 10 nM in sensitive models. In vivo, Surzetoclax causes rapid tumor regression in xenograft models of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is orally bioavailable and demonstrates dose-dependent target engagement with favorable pharmacokinetics. Compared to Venetoclax, Surzetoclax was designed to reduce risks of tumor lysis syndrome and other dose-limiting toxicities.
MedKoo Cat#: 126560
Name: Surzetoclax
CAS#: 2858632-01-4
Chemical Formula: C53H63ClN8O10S
Exact Mass: 1038.4076
Molecular Weight: 1039.64
Elemental Analysis: C, 61.23; H, 6.11; Cl, 3.41; N, 10.78; O, 15.39; S, 3.08
The following data is based on the product molecular weight 1,039.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
